Global Health's Executive Director and former CEO, Mathew Cherian, presented at the Proactive Lifesciences investor webinar earlier today to show off the company's latest investor presentation.
The key highlights addressed by Mr Cherian included the companies latest $7.8m placement with Bell Potter and Baker Young, a placement that will provide the company with a strong cash position to target a 70-80% annual recurring revenue growth in 2021, as well as the appointment of Michael Davies as the companies new CEO.
Global Health was one of three ASX listed companies to present their upcoming plans and strategies for 2021 at the webinar, alongside Noxopharm Ltd (ASX:NOX) and Compumedics Ltd (ASX:CMP).
You can view the full presentation by clicking here.
